Ahad A. Sadiq

2.4k total citations · 1 hit paper
17 papers, 1.6k citations indexed

About

Ahad A. Sadiq is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ahad A. Sadiq has authored 17 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Ahad A. Sadiq's work include Lung Cancer Treatments and Mutations (9 papers), Cancer Immunotherapy and Biomarkers (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Ahad A. Sadiq is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Cancer Immunotherapy and Biomarkers (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Ahad A. Sadiq collaborates with scholars based in United States, United Kingdom and Israel. Ahad A. Sadiq's co-authors include Ravi Salgia, Michael McCleod, Howard West, Federico Cappuzzo, Henry Jacob Conter, Davey B. Daniel, Hans‐Georg Kopp, Venice Archer, Alan Sandler and Wei Lin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Ahad A. Sadiq

17 papers receiving 1.5k citations

Hit Papers

Atezolizumab in combinati... 2019 2026 2021 2023 2019 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
    2019 1.1k citations Howard West, Michael McCleod et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ahad A. Sadiq United States 9 1.3k 1.0k 223 204 147 17 1.6k
Steven McCune United States 10 1.1k 0.9× 815 0.8× 240 1.1× 330 1.6× 112 0.8× 19 1.6k
Etienne Giroux‐Leprieur France 23 1.0k 0.8× 706 0.7× 194 0.9× 492 2.4× 252 1.7× 77 1.5k
Jianchun Duan China 16 732 0.6× 367 0.4× 195 0.9× 274 1.3× 146 1.0× 59 1.1k
Tatsuro Fukuhara Japan 19 1.1k 0.9× 1.1k 1.1× 127 0.6× 445 2.2× 318 2.2× 55 1.6k
Si-Pei Wu China 13 941 0.7× 659 0.6× 300 1.3× 544 2.7× 386 2.6× 23 1.5k
Federica Biello Italy 20 634 0.5× 418 0.4× 154 0.7× 267 1.3× 292 2.0× 56 994
Hidenobu Ishii Japan 15 1.0k 0.8× 692 0.7× 185 0.8× 166 0.8× 217 1.5× 55 1.3k
Xuezhi Hao China 21 733 0.6× 690 0.7× 68 0.3× 372 1.8× 216 1.5× 114 1.1k
Paola Bordi Italy 17 800 0.6× 798 0.8× 136 0.6× 413 2.0× 353 2.4× 51 1.2k

Countries citing papers authored by Ahad A. Sadiq

Since Specialization
Citations

This map shows the geographic impact of Ahad A. Sadiq's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ahad A. Sadiq with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ahad A. Sadiq more than expected).

Fields of papers citing papers by Ahad A. Sadiq

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ahad A. Sadiq. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ahad A. Sadiq. The network helps show where Ahad A. Sadiq may publish in the future.

Co-authorship network of co-authors of Ahad A. Sadiq

This figure shows the co-authorship network connecting the top 25 collaborators of Ahad A. Sadiq. A scholar is included among the top collaborators of Ahad A. Sadiq based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ahad A. Sadiq. Ahad A. Sadiq is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Samaniego, Felipe, Ahad A. Sadiq, Daruka Mahadevan, et al.. (2022). A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies. Blood. 140(Supplement 1). 6498–6500. 1 indexed citations
3.
4.
West, Howard, Michael McCleod, Maen Hussein, et al.. (2019). Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 20(7). 924–937. 1137 indexed citations breakdown →
5.
Joshi, Smita S., Daniel V.T. Catenacci, Theodore Karrison, et al.. (2019). Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype–Guided Dosing. Clinical Cancer Research. 26(1). 18–24. 9 indexed citations
6.
7.
Durm, Greg Andrew, Sandra K. Althouse, Ahad A. Sadiq, et al.. (2018). Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.. Journal of Clinical Oncology. 36(15_suppl). 8500–8500. 43 indexed citations
8.
Jacobson, Blake A., Mark S. Peterson, Marian G. Kratzke, et al.. (2017). 4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma. Investigational New Drugs. 36(2). 217–229. 11 indexed citations
9.
Durm, Greg Andrew, Cynthia S. Johnson, Shadia I. Jalal, et al.. (2017). Safety and feasibility of consolidation pembrolizumab following concurrent chemoradiation for unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN14-179.. Journal of Clinical Oncology. 35(15_suppl). 8523–8523. 8 indexed citations
10.
Jacobson, Blake A., Ahad A. Sadiq, Shaogeng Tang, et al.. (2017). Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma. Oncotarget. 8(38). 63096–63109. 7 indexed citations
11.
Patel, Manish R., Blake A. Jacobson, Ahmad Raza, et al.. (2014). Measles Vaccine Strains for Virotherapy of Non–Small-Cell Lung Carcinoma. Journal of Thoracic Oncology. 9(8). 1101–1110. 29 indexed citations
12.
Patel, Manish R., et al.. (2013). Resistance to EGFR-TKI Can Be Mediated through Multiple Signaling Pathways Converging upon Cap-Dependent Translation in EGFR-Wild Type NSCLC. Journal of Thoracic Oncology. 8(9). 1142–1147. 8 indexed citations
13.
Sadiq, Ahad A. & Ravi Salgia. (2013). MET As a Possible Target for Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 31(8). 1089–1096. 152 indexed citations
14.
15.
Sadiq, Ahad A. & Ravi Salgia. (2012). Inhibition of MET Receptor Tyrosine Kinase and Its Ligand Hepatocyte Growth Factor. Journal of Thoracic Oncology. 7(12). S372–S374. 3 indexed citations
16.
Sadiq, Ahad A., Daniel M. Geynisman, & Ravi Salgia. (2011). Inhibition of MET Receptor Tyrosine Kinase and Its Ligand Hepatocyte Growth Factor. Journal of Thoracic Oncology. 6(11). S1810–S1811. 6 indexed citations
17.
Sadiq, Ahad A., Manish R. Patel, Blake A. Jacobson, et al.. (2009). Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II. Investigational New Drugs. 28(1). 20–25. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven McCune Breakdown of academic impact, for papers by Etienne Giroux‐Leprieur Breakdown of academic impact, for papers by Jianchun Duan Breakdown of academic impact, for papers by Tatsuro Fukuhara Breakdown of academic impact, for papers by Si-Pei Wu Breakdown of academic impact, for papers by Federica Biello Breakdown of academic impact, for papers by Hidenobu Ishii Breakdown of academic impact, for papers by Xuezhi Hao Breakdown of academic impact, for papers by Paola Bordi
Rankless by CCL
2026